Danaher is trading 14.2% down today at $172.57 after releasing second-quarter 2026 results and updating its full-year outlook.
- While the company beat earnings and revenue estimates and raised its full-year EPS guidance, it trimmed the upper end of its core revenue growth range.
- The negative market reaction is primarily driven by weaker-than-expected biotechnology revenue, which overshadowed the positive earnings surprise.